Dossier assessment

Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-145
Last updated

Report documents

  1. Extract of dossier assessment

    Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 755 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-145_en
  2. Dossier assessment

    Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-145

Drug assessment at a glance

  1. Drug assessment at a glance

    Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 252 kB, EN, not accessible

Dossier assessment

Indication:

Add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

07-05-2026 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-145
Commission
Commission awarded on 17.11.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-145_en

Connected Projects

  1. Dossier assessment

    Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-122
    Last updated

    Status: Commission completed

  2. Addendum

    Tezepelumab (chronic rhinosinusitis with nasal polyps) – Addendum to Project A25-145

    Project no.
    A26-32
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form